Trial · NCT07603700
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
NCT07603700, Not yet recruiting, Nanjing First Hospital, Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism. Trials, record NCT07603700. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07603700
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
- NCT number
- NCT07603700
- Status
- Not yet recruiting
- Enrollment
- 1,300 participants, estimated
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
- Conditions
- Pulmonary Embolism, Venous Thromboembolism
- Interventions
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- First posted
- 2026-05-22
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All-Cause Mortality at 30 Days | 30 days | The percentage of participants who die from any cause within 30 days of enrollment. |
| Primary | All-Cause Mortality at 90 Days | 90 days | The percentage of participants who die from any cause within 90 days of enrollment. |
| Primary | Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours | 48 hours ± 6 hours | The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography. |
| Secondary | Major Bleeding Events | 48 hours, 7 days, 30 days, 90 days | Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage). |
| Secondary | Clinical Deterioration | 48 hours, 7 days | Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death. |
| Secondary | 6-Minute Walk Test (6MWT) Distance | 30 days, 90 days | Change in walking distance from baseline (estimated) to follow-up. Minimal Clinically Important Difference (MCID) ≥30 meters. |
| Secondary | Post-VTE Functional Status (PVFS) Score | 30 days, 90 days | Assessment of functional limitation due to VTE (Scale 0-5). |
| Secondary | Quality of Life (PEmb-QoL) | 90 days | The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease. |
| Secondary | Symptomatic PE Recurrence | 90 days | Confirmed recurrent PE via CTPA or V/Q scan. |
| Secondary | ICU Length of Stay | From ICU admission to ICU discharge, assessed up to 30 days | Duration of intensive care unit stay during the index hospitalization |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07603700
GET https://conductscience.org/api/trials/v1/NCT07603700/registered